EU drugs watchdog on Thursday recommended to adopt preventive cocktail Covid-19 AstraZeneca, which can be used for patients with severe immune system reaction to the vaccine or other coronavirus.
Committee for human medicines European Medicines Agency “has recommended the granting of marketing authorization for Evusheld, developed by AstraZeneca for the prevention Covid-19 in adults and adolescents from 12 years of age,” said Amsterdam-based EMA in a statement.
Evusheld consists of two monoclonal antibodies tixagevimab and cilgavimab – proteins that are designed to attack the virus spike protein of SARS-CoV-2 which causes Covid-19 – at two different sites, according to the EMA.
He said data from tests on 5,000 people who were given two glances, showed it reduced the risk of infection Covid-19 by 77 per cent and the protection lasts for at least six months.
The survey was done on adults who had never had Covid-19 and have never received the vaccine or other preventive treatment, EMA says.
“Evusheld safety profile is good and the side effects are generally mild, with a small number of people have reported reactions at the injection site or hypersensitivity,” added the drug watchdog.
But the study was done before the emergence of strains of an infectious virus Omicron and “laboratory studies show that the variant Omicron A.1 may be less sensitive to tixagevimab and cilgavimab compared Omicron variant A.2,” the foreman said.
The EMA recommendation will now be forwarded to the European Commission for final approval before being distributed to a 27 -member bloc.
Evusheld received emergency clearance from the U.S. -based FDA in December.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)